DK1535623T3 - Nyrecelle-carcinom behandling - Google Patents

Nyrecelle-carcinom behandling

Info

Publication number
DK1535623T3
DK1535623T3 DK05002952T DK05002952T DK1535623T3 DK 1535623 T3 DK1535623 T3 DK 1535623T3 DK 05002952 T DK05002952 T DK 05002952T DK 05002952 T DK05002952 T DK 05002952T DK 1535623 T3 DK1535623 T3 DK 1535623T3
Authority
DK
Denmark
Prior art keywords
cell carcinoma
renal cell
carcinoma treatment
treatment
renal
Prior art date
Application number
DK05002952T
Other languages
Danish (da)
English (en)
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1535623T3 publication Critical patent/DK1535623T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK05002952T 1999-04-08 2000-04-06 Nyrecelle-carcinom behandling DK1535623T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08
PCT/US2000/009127 WO2000061174A2 (en) 1999-04-08 2000-04-06 Use of pegylated interferon alpha for renal cell carcinoma treatment

Publications (1)

Publication Number Publication Date
DK1535623T3 true DK1535623T3 (da) 2009-04-27

Family

ID=23106761

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00107100T DK1043025T3 (da) 1999-04-08 2000-04-06 Behandling af nyrecellekarcinom
DK05002952T DK1535623T3 (da) 1999-04-08 2000-04-06 Nyrecelle-carcinom behandling

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK00107100T DK1043025T3 (da) 1999-04-08 2000-04-06 Behandling af nyrecellekarcinom

Country Status (24)

Country Link
EP (2) EP1535623B1 (ja)
JP (2) JP3712914B2 (ja)
CN (1) CN1367702A (ja)
AR (1) AR029160A1 (ja)
AT (2) ATE296638T1 (ja)
AU (2) AU777406B2 (ja)
BR (1) BR0009644A (ja)
CA (1) CA2303752A1 (ja)
CO (1) CO5170412A1 (ja)
CY (1) CY1108919T1 (ja)
DE (2) DE60020442T2 (ja)
DK (2) DK1043025T3 (ja)
ES (2) ES2319777T3 (ja)
HK (2) HK1032533A1 (ja)
HU (1) HU230271B1 (ja)
MX (1) MXPA00003401A (ja)
MY (1) MY155221A (ja)
NO (1) NO328983B1 (ja)
NZ (1) NZ514629A (ja)
PE (1) PE20010026A1 (ja)
PT (2) PT1535623E (ja)
TW (2) TW200526243A (ja)
WO (1) WO2000061174A2 (ja)
ZA (1) ZA200108169B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230271B1 (hu) * 1999-04-08 2015-11-30 Merck Sharp & Dohme Corp Pegilezett alfa-interferon alkalmazása vesesejt-karcinóma kezelésére
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
ES2891564T3 (es) 2010-04-01 2022-01-28 Oncorena Ab Tratamiento mejorado del carcinoma de células renales
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU754002B2 (en) * 1998-03-26 2002-10-31 Merck Sharp & Dohme Corp. Formulations for protection of peg-interferon alpha conjugates
HU230271B1 (hu) * 1999-04-08 2015-11-30 Merck Sharp & Dohme Corp Pegilezett alfa-interferon alkalmazása vesesejt-karcinóma kezelésére

Also Published As

Publication number Publication date
TWI310314B (en) 2009-06-01
HUP0200781A3 (en) 2002-09-30
ES2319777T3 (es) 2009-05-12
PT1043025E (pt) 2005-09-30
EP1043025A2 (en) 2000-10-11
CO5170412A1 (es) 2002-06-27
WO2000061174A2 (en) 2000-10-19
ATE419002T1 (de) 2009-01-15
AR029160A1 (es) 2003-06-18
DE60041291D1 (de) 2009-02-12
DK1043025T3 (da) 2005-07-04
CY1108919T1 (el) 2014-07-02
HUP0200781A2 (en) 2002-08-28
EP1535623A1 (en) 2005-06-01
HK1075417A1 (en) 2005-12-16
EP1043025A3 (en) 2000-12-20
HU230271B1 (hu) 2015-11-30
EP1043025B1 (en) 2005-06-01
BR0009644A (pt) 2002-01-08
ES2239953T3 (es) 2005-10-16
JP4721488B2 (ja) 2011-07-13
EP1535623B1 (en) 2008-12-31
CN1367702A (zh) 2002-09-04
DE60020442D1 (de) 2005-07-07
PT1535623E (pt) 2009-03-19
DE60020442T2 (de) 2006-05-04
AU777406B2 (en) 2004-10-14
AU2004242454B2 (en) 2007-02-15
AU2004242454A1 (en) 2005-01-20
JP2000319196A (ja) 2000-11-21
HK1032533A1 (en) 2001-07-27
NO328983B1 (no) 2010-07-05
MY155221A (en) 2015-09-30
NO20014851L (no) 2001-12-07
ZA200108169B (en) 2003-01-06
NZ514629A (en) 2004-02-27
PE20010026A1 (es) 2001-02-05
CA2303752A1 (en) 2000-10-08
ATE296638T1 (de) 2005-06-15
JP2001288110A (ja) 2001-10-16
JP3712914B2 (ja) 2005-11-02
AU4204400A (en) 2000-11-14
WO2000061174A3 (en) 2001-01-25
TW200526243A (en) 2005-08-16
NO20014851D0 (no) 2001-10-05
MXPA00003401A (es) 2002-03-08

Similar Documents

Publication Publication Date Title
DE10084903T1 (de) Polyetherpolyurethan
DE60001530T2 (de) Verbinder
DE60006630D1 (de) Verbinder
DE60020922D1 (de) Verbinder
DE60042231D1 (de) Verbinder
DE69920862D1 (de) Verbinder
DE60008069D1 (de) Verbinder
DE60026459D1 (de) Simethicon enthaltendes Abführmittel
DE60019059D1 (de) Verbinder
DE60001032D1 (de) Verbinder
DE60037233D1 (de) Hämofiltrationsvorrichtung
DE60043606D1 (de) Verbinder
DE60025681D1 (de) Verbinder
DE60027520D1 (de) Verbinder
DE60015473D1 (de) Verbinder
DE60026234D1 (de) Verbinder
DE60001783D1 (de) Verbinder
HK1075417A1 (en) Renal cell carcinoma treatment
DE60003993D1 (de) Verbinder
DE60007475D1 (de) Filter
DE60017062D1 (de) Verbinder
DE60014496D1 (de) Verbinder
DE60012162D1 (de) Verbinder
DE60009806D1 (de) Verbinder
BR0009400B1 (pt) unidade filtrante do tipo célula.